TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Science Immunology · 19.04.2024 · 9 (94)
DOI: 10.1126/sciimmunol.adg1094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 19.04.2024. Verfasst von Simone A Minnie und 20 weiteren Autor:innen. Beteiligte Einrichtung: Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematologic Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Pediatrics, University of Washington, Seattle, WA, USA.
- Department of Hematology/Medical Oncology, Emory University, Atlanta, GA, USA.
- Winship Cancer Institute, Emory University, Atlanta, GA, USA.
- Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA.
- Division of Medical Oncology, University of Washington, Seattle, WA, USA.
ORCID-Profile: Simone A Minnie, Olivia G Waltner, Ping Zhang, Shuichiro Takahashi, Christine R Schmidt, Melissa Comstock, Julie R Boiko, Alec B Wilkens, Motoko Koyama, Madhav V Dhodapkar, Marta Chesi, Stanley R Riddell, Damian J Green, Andrew Spencer, Scott N Furlan, Geoffrey R Hill
Förderung
- NCI NIH HHS
- NIH HHS
- NCATS NIH HHS
Zitieren
APA
Minnie, S. A., Waltner, O. G., Zhang, P., Takahashi, S., Nemychenkov, N. S., Ensbey, K. S., Schmidt, C. R., Legg, S. R. W., Comstock, M., Boiko, J. R., Nelson, E., Bhise, S. S., Wilkens, A. B., Koyama, M., Dhodapkar, M. V., Chesi, M., Riddell, S. R., Green, D. J., Spencer, A., …, & Hill, G. R. (2024). TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. Science Immunology, 9(94). https://doi.org/10.1126/sciimmunol.adg1094
Vancouver
Minnie SA, Waltner OG, Zhang P, Takahashi S, Nemychenkov NS, Ensbey KS, et al. TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. Science Immunology. 2024;9(94). doi:10.1126/sciimmunol.adg1094
BibTeX
@article{Minnie2024,
author = {Minnie, Simone A and Waltner, Olivia G and Zhang, Ping and Takahashi, Shuichiro and Nemychenkov, Nicole S and Ensbey, Kathleen S and Schmidt, Christine R and Legg, Samuel R W and Comstock, Melissa and Boiko, Julie R and Nelson, Ethan and Bhise, Shruti S and Wilkens, Alec B and Koyama, Motoko and Dhodapkar, Madhav V and Chesi, Marta and Riddell, Stanley R and Green, Damian J and Spencer, Andrew and Furlan, Scott N and Hill, Geoffrey R},
title = {TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies},
journal = {Science Immunology},
year = {2024},
volume = {9},
number = {94},
doi = {10.1126/sciimmunol.adg1094}
}
EUVIMED